Overview:

The study involved four major activities in estimating the current size of the Cardiac Mapping Market. Exhaustive secondary research was done to collect information on the market and its different subsegments.

The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the total market size. After that, the market breakdown and data triangulation was used to estimate the market size of segments and subsegments

Recent Developments:

# In 2019, Acutuc medical partnered with Peerbridge Health, US. Under the partnership, Peerbridge Health offered its advanced ambulatory ECG—Peerbridge Cor that has been cleared to detect up to 26 different arrhythmias to be used with the AcQMap System.

# In 2018, Royal Philips acquired EPD Solutions, Israel, an innovator in image-guided procedures for cardiac arrhythmias.

Key Players:

The major players in the cardiac mapping market include Biosense Webster (US), Abbott (US),  Medtronic (Ireland), Boston Scientific Corporation (US), MicroPort Scientific Corporation (China), EP Solutions SA (Switzerland), Acutus Medical (US), Koninklijke Philips N.V. (Royal Philips) (Netherlands), Lepu Medical  (China), BIOTRONIK (Germany), AngioDynamics (US), BioSig Technologies (US), APN Health (US), CoreMap (US), Kardium (Canada), Catheter Precision (US), and Epmap-System  (Germany).

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=89853405

Different Growth Strategies Adopted by Them:

The analysis of market developments between 2017 and 2019 showed that market players adopted strategies such as product launches, approvals, partnerships, agreements, collaborations, acquisitions, and other developments to strengthen their product portfolios and maintain a competitive position in the cardiac mapping systems market.

More About Key Players:

Boston Scientific Corporation (US) held the third-largest share of the cardiac mapping market in 2018. The company provides a cardiac mapping system along with ablation-mapping catheters. The company’s Rhythmia Mapping System is indicated for catheter-based atrial and ventricular mapping, which allows real-time visualization of intracardiac catheters as well as the display of cardiac maps in a number of different formats. Moreover, Boston Scientific has a strong geographic presence in more than 40 countries globally. In March 2016, the company collaborated with Mayo Clinic, US, to share intellectual property ideas for the development of new medical devices to address unmet clinical needs.

Abbott (US) held the second-largest share of the cardiac mapping market in 2018. The company offers an advanced EnSite Precision cardiac mapping system, along with sensor-enabled catheters compatible with the mapping system. The firm’s Cardiovascular and Neuromodulation Products segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases.

The firm focuses on organic inorganic growth strategies. For instance, in 2018, the company received the US FDA approval for its Advisor HD Grid Mapping Catheter, Sensor Enabled, which can help optimize the accuracy of the cardiac image when paired with the EnSite Precision cardiac mapping system. Moreover, the company acquired St. Jude Medical (US), in 2017, thus expanding its product portfolio in cardiac rhythm management and electrophysiology market.

Biosense Webster (US) held the dominant position in the cardiac mapping market in 2018. The large share of this company can be attributed to its strong suite of cardiac mapping systems, software, and catheters. The company provides products mainly targeted at the diagnosis and treatment of several cardiac arrhythmias, such as atrial fibrillation. Moreover, the firm has a strong geographic presence in all regions of the world. The company focuses on product launches to create a strong foothold in the market. In 2019, Biosense introduced the CARTONET, a cloud-based networking and data analytics software solution.

North America is expected to hold a dominant share in the cardiac mapping market during the forecast period

North America held the largest share of the market in 2019 and is projected to continue to do so during the forecast period. Factors such as the increase in approval rate of mapping systems and clinical trials validating cardiac mapping systems in the US, high incidence of CVDs, growing focus of government organizations on providing funding for research, and increasing geriatric population in Canada are driving the North American cardiac mapping market.

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=89853405